Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology

1 Executive Summary

2 Cancer Highlights

3 Methodology

4 4.1 List of Boxes
4.2 List of Figures
4.3 List of Tables

5 Introduction
5.1 Neoplastic Angiogenesis & Tumor Vasculature
5.1.1 Tumor Vasculature
5.1.2 The Current Model of Sprouting Angiogenesis
5.2 Main Angiogenic Factors
5.2.1 Vascular Endothelial Growth Factor
5.2.2 The Angiopoietins and Platelet Derived Growth Factor
5.2.3 Integrins in Angiogenesis
5.2.4 Inhibitors of Angiogenesis
5.3 Vascular Targeting Agents
5.4 Vascular Disruptive Agents

6 Competitive Landscape in Anti-Angiogenesis and Vascular Targeting in Oncology
6.1 Countries & Players: Who are In the Lead?
6.1.1 Top 10 Players Dominate The Developmental Pipeline
6.2 Deals & Alliances in Anti-Angiogenesis and Vascular Targeting
6.2.1 Review of Deals and Alliances Initiated in 2005
6.2.2 Review of Deals and Alliances Initiated in 2004
6.2.3 Review of Deals and Alliances Initiated in 2003

7 Approved Anti-Angiogenic Cancer Drugs: Performance

8 Target Analysis in Anti-Angiogenesis and Vascular Targeting
8.1 Targets of Late Stage Anti-Angiogenic Drugs in Development
8.1.1 Drugs with Epidermal Growth Factor Receptor as a Target
8.1.2 Drugs with FMS-related Tyrosine Kinase 1 as a Target
8.1.3 Drugs with FMS-related Tyrosine Kinase 4 as a Target
8.1.4 Drugs with Kinase Insert Domain Receptor as a Target
8.1.5 Drugs with Phosphodiesterase 2A, cGMP-stimulated as a Target
8.1.6 Drugs with Phosphodiesterase 5A, cGMP-specific as a Target
8.1.7 Drugs with Patelet-Derived Growth Factor Receptor, alpha Polypeptide as a Target
8.1.8 Drugs with Platelet-Derived Growth Factor, beta Polypeptide as a Target
8.1.9 Drugs with Protein Kinase C, beta 1 as a Target
8.1.10 Drugs with Ret Proto-Oncogene as a Target
8.1.11 Drugs with v-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog as a
Target
8.1.12 Drugs with v-raf-1 Murine Leukemia Viral Oncogene Homolog 1 as a Target
8.1.13 Drugs with Vascular Endothelial Growth Factor as a Target

8.2 Anti-Angiogenic Drugs and Their Targets According to Top 5 Cancer Indications
8.2.1 Targets in Breast Cancer
8.2.2 Targets in Colorectal Cancer
8.2.3 Targets in Lung Cancer
8.2.4 Targets in Prostate Cancer
8.2.5 Targets in Renal Cancer

9 Anti-angiongenesis and Vascular Targeting Drugs in Development: By Major Indications
9.1 General Drug Developmental Overview
9.2 Progress Analysis – Breast Cancer
9.2.1 Phase I Clinical Development.
9.2.2 Phase II Clinical Development
9.2.3 Phase III Clinical Development
9.3 Progress Analysis – Colorectal Cancer
9.3.1 Phase I Clinical Development
9.3.2 Phase II Clinical Development
9.3.3 Phase III Clinical Development
9.4 Progress Analysis – Lung Cancer
9.4.1 Phase I Clinical Development
9.4.2 Phase II Clinical Development
9.4.3 Phase III Clinical Development
9.5 Progress Analysis – Prostate Cancer
9.5.1 Phase I Clinical Development
9.5.2 Phase II Clinical Development
9.5.3 Phase III Clinical Development
9.6 Progress Analysis – Renal Cancer
9.6.1 Phase I Clinical Development
9.6.2 Phase II Clinical Development
9.6.3 Phase III Clinical Development

10 Disclaimer
10.1 Liability
10.2 Completeness

11 Appendix I: Complete List of Angiogenic and Vascular Target Agents in Development in Oncology

12 Drug Index

13 Company Index

4.1 List of Boxes
Box 1: Nexavar’s Clinical Data That Lead To Its EMEA Approval Myeloma
Box 2: Thalomid Delays Time to Disease Progression in Newly Diagnosed Multiple Myeloma
Box 3: Strong Clinical Data Suggests Approval to Market Avastin For The Treatment of Both Breast Cancer and NSCLC
Box 4: Avastin Fails to Meet Primary Endpoint in Advanced Pancreatic Cancer
Box 5: Business & Market – Cilengitide
Box 6: Business & Market – Exherin
Box 7: Business & Market – WX-UK1
Box 8: Business & Market – Combretastatin A-4 phosphate
Box 9: Business & Market – GCS-100LE
Box 10: Business & Market – PTK/ZK
Box 11: Business & Market – AS-1404
Box 12: Business & Market – Phosphomannopentaose sulfate
Box 13: Business & Market – Squalamine
Box 14: Business & Market – talactoferrin alfa
Box 15: Business & Market – ZD-6474
Box 16: Business & Market – AP-23573
Box 17: Business & Market – Volociximab
Box 18: Business & Market – XL-999

4.2 List of Figures
Figure 1: Establishment of Blood Supply to Tumors
Figure 2: Sprouting Angiogenesis
Figure 3: Top 5 Countries in Cancer Angiogenesis and Vascular Targeting Research
Figure 4: Top 10 Companies’ Clinical Trial Progress in Anti-Angiogenesis and Vascular Targeting
Figure 5: Deals & Alliances in Anti-Angiogenesis and Vascular Targeting 2001-2005
Figure 6: Annual Sales of Avastin on US and Non US Markets
Figure 7: Trial Distribution of the Entire Anti-Angiogenic and Vascular Target Agent Field in Oncology
Figure 8: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Breast Cancer
Figure 9: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Colorectal
Figure 10: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Lung Cancer
Figure 11: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Prostate Cancer
Figure 12: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Renal Cancer

4.3 List of Tables
Table 1: Top 10’s Anti-angiogenic and Vascular Targeting Pipeline Drugs
Table 2: Deals & Alliances in 2005
Table 3: Deals & Alliances in 2004
Table 4: Deals & Alliances in 2003
Table 5: Companies with Cancer Anti-angiogenic Drugs on the Market
Table 6: 2006 Q2 Sales Revlimid and Thalomid
Table 7: 2006 Q2 Sales of Avastin
Table 8: List of 75 Known Targets in Ant-angiogenis and Vascular Targeting in Drug Development
Table 9: Known Targets of Late Stage Anti-Angiogenic Drugs in Development
Table 10: Drugs with Epidermal Growth Factor Receptor as a Target
Table 11: Drugs with FMS-related Tyrosine Kinase 1 as a Target
Table 12: Drugs with FMS-related Tyrosine Kinase 4 as a Target
Table 13: Drugs with Kinase Insert Domain Receptor as a Target
Table 14: Drugs with Phosphodiesterase 2A, cGMP-stimulated as a Target
Table 15: Drugs with Phosphodiesterase 5A, cGMP-specific as a Target
Table 16: Drugs with Patelet-Derived Growth Factor Receptor, alpha Polypeptide as a Target
Table 17: Drugs with Platelet-Derived Growth Factor, beta Polypeptide as a Target
Table 18: Drugs with Protein Kinase C, beta 1 as a Target
Table 19: Drugs with Ret Proto-Oncogene as a Target
Table 20: Drugs with v-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog as a Target
Table 21: Drugs with v-raf-1 Murine Leukemia Viral Oncogene Homolog 1 as a Target
Table 22: Drugs with Vascular Endothelial Growth Factor as a Target
Table 23: Breast Cancer Targets in Anti-Angiogenic Drug Development
Table 24: Colorectal Cancer Targets in Anti-Angiogenic Drug Development
Table 25: Lung Cancer Targets in Anti-Angiogenic Drug Development
Table 26: Prostate Cancer Targets in Anti-Angiogenic Drug Development
Table 27: Renal Cancer Targets in Anti-Angiogenic Drug Development
Table 28: Top 10 Cancer Indications in Anti-Angiogenesis and Vascular Targeting Cancer Drugs
Table 29: Recent Ceased or Discountinued Phase I to Phase III Anti-angiogenic and Vascular Targeting Drugs
Table 30: Overview of Drugs in Phase III Clinical Development
Table 31: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Breast Cancer
Table 32: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Colorectal Cancer
Table 33: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Lung Cancer
Table 34: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Prostate Cancer
Table 35: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Renal Cancer